

A De Novo AI–Physics Platform for Scalable Therapeutic Asset Generation

The maximum number of words for this abstract is 400, 60 words/section.

Please be sure to complete the following:

Company name-**DenovAI Biotech Ltd.**- * Website-**www.denovai.com**- *

Founder & CEO name-**Kashif Sadiq**-* Cell phone number & Email-**kashif@denovai.com**- *

Deck will be presented by Tal Leibovich, Co founder and COO

Select one SESSION per abstract from the list below *

Session #10. **“AI Pharma” Drug Discovery, Quantum Computing**

Executive Summary / Investment Rationale

DenovAI is developing an asset discovery engine; a proprietary AI–physics-platform for de novo biologics discovery, enabling one-shot design of therapeutic candidates from scratch. The company targets the rapidly growing biologics market, aiming to bring first-in-class and best-in-class therapeutics to patients, faster. Founded at AION Labs, DenovAI collaborates with leading pharma partners, validating its technology through strategic discovery programs at the highest industry-standards.

Core Technology

DenovAI combines generative AI, molecular biophysics, and automated workflows to design biologics bypassing large-scale screening. The platform is target- and modality-agnostic, integrating sequence, structure, kinetics and function into a unified discovery engine that enables rapid generation of optimized miniproteins, antibodies, multispecifics, and novel protein modalities - right from get-go, lowering costly and iterative discovery efforts.

Product Profile / Pipeline

DenovAI is advancing a pipeline of de novo biologics across oncology, immunology and inflammatory indications. The company focuses on challenging targets with validated biology, aiming at progressing selected assets from discovery until IND-enabling. De-novo discovery and novel drug modalities support strong FTO in the current sequence and structure space.

Business Strategy

DenovAI’s proprietary asset-generation engine drives a business model centred on internal pipeline creation alongside selective strategic co-discovery partnerships. Near-term revenues are supported through pharma collaborations, while long-term value is built through proprietary therapeutic assets and downstream program economics. The company continues to expand its platform through multifeatured and multimodal AI capabilities as well as growing support for diverse therapeutic modalities.